Narlaprevir
|
|
|
- CAS-Nr.
- 865466-24-6
- Englisch Name:
- Narlaprevir
- Synonyma:
- Sch 900518;Narlaprevir;Sch 900518 Narlaprevir;Narlaprevir(SCH 900518 );SCH 900518;SCH900518;SCH-900518;(1R,2S,5S)-N-[(1S)-1-[(Cyclopropylamino)oxoacetyl]pentyl]-3-[(2S)-2-[[[[1-[[(1,1-dimethylethyl)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]pentyl]-3-[(2S)-2-[[[[1-[[(1,1-dimethylethyl)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-, (1R,2S,5S)-
- CBNumber:
- CB52554290
- Summenformel:
- C36H61N5O7S
- Molgewicht:
- 707.96
- MOL-Datei:
- 865466-24-6.mol
|
Narlaprevir Eigenschaften
- Schmelzpunkt:
- 152 - 155°C
- Dichte
- 1.21
- storage temp.
- Hygroscopic, -20°C Freezer, Under inert atmosphere
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- pka
- 11.84±0.20(Predicted)
- Farbe
- White to Off-White
- Stabilität:
- Hygroscopic
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P301+P312 |
BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P302+P352 |
BEI BERÜHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckmäßig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Narlaprevir Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Narlaprevir was approved as a
treatment for genotype 1 HCV and serves as a class 2 HCV
NS3 serine protease inhibitor. In clinical trials, it showed a
rapid and steady decline in HCV-RNA levels in both previously
treated and treatment-naive patients when used in combination
with ritonavir and PEG-IFN-α. This combination ultimately
led to ≥50% of patients with undetectable HCV-RNA levels
after a second period of treatment. Narlaprevir also has
demonstrated activity against HCV mutations resistant to other
treatments such as boceprevir and telaprevir. The unique
activity of this drug can be attributed to a critical electrophilic
α-keto-amide “warhead”, which covalently reacts with an HCV
NS3 protease active-site serine residue involved in the HCV
viral replication process. Because of their essential roles in
viral replication, HCV NS3 and NS5B proteases have recently
become key targets for HCV drug development. Strategically,
the development of narlaprevir stems specifically from the
pursuit of a single-diastereomer, second generation HCV
protease inhibitor, which would provide in vitro potency and
pharmacokinetic profile improvements over the structurally
related antiviral drug boceprevir,which exists as a mixture of
diastereomers. After the R-Pharm pharmaceutical group
obtained the license to manufacture narlaprevir from Merck in
2012, further development of the drug was realized through
collaborations with Schering-Plough and Texas Liver Institute.
Verwenden
Narlaprevir is an NS3/4A protease inhibitor used in the treatment of hepatitis C virus, HCV.
Narlaprevir Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Narlaprevir Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 46)Lieferanten
- (1R,2S,5S)-N-[(1S)-1-[(Cyclopropylamino)oxoacetyl]pentyl]-3-[(2S)-2-[[[[1-[[(1,1-dimethylethyl)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
- Narlaprevir
- Sch 900518
- Sch 900518 Narlaprevir
- Narlaprevir(SCH 900518 )
- SCH 900518;SCH900518;SCH-900518
- 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]pentyl]-3-[(2S)-2-[[[[1-[[(1,1-dimethylethyl)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-, (1R,2S,5S)-
- 865466-24-6
- C36H61N5O7S
